Androgen Deprivation Therapy and Risk of SARS-CoV-2 Infection in Men With Prostate Cancer: A University of California Health System Registry Study

ABSTRACT

Association of the Clinical Cell-Cycle Risk Score With Metastasis After Radiation Therapy and Identification of Men With Prostate Cancer Who Can Forgo Combined Androgen Deprivation Therapy Tward and colleagues examined the ability to identify individuals with localized prostate cancer with such a low risk for metastasis following dose-escalated radiation therapy that there is no benefit to adding ADT ( 195). A combined clinical cell-cycle risk score (CCR) combines the cell cycle progression score (CCP) with the UCSF Cancer of the Prostate Risk Assessment score (CAPRA). The CCR was found to be a significant predictor of metastasis (HR, 2.21;95% CI, 1.70-2.87;P=5.6×10–9). The CCR score continued to be highly predictive for metastasis in bivariate analyses when comparing ADT use vs none (HR, 2.19;95% CI, 1.68-2.84;P=1.0 × 10–8) or ADT duration as a continuous variable (HR, 2.11;95% CI, 1.59-2.79;P=3.0×10–7). Patients with CCR scores below the identified threshold of 2.112 had less than a 5% risk for 10-year metastasis regardless of ADT use (overall, sufficient ADT, radiation therapy with any duration of ADT, or radiation therapy alone with no ADT) or National Comprehensive Cancer Network risk group (favorable intermediate risk, unfavorable intermediate risk, or high/very high risk).